That study discusses other aspects of the technology too, including these:
• Funding for biomarker discovery and research
• Validation of biomarkers in oncology
• Mergers and acquisitions (M&A)
• Alliances, partnerships, collaborations, and licensing
• Interest from pharma companies, inc. Pfizer, Novartis, Merck, Sanofi, and Roche.
There you explore political, economic, social, and technological questions, assessing outlooks for business. See, then, what restrains and what helps the biomarkers industry.
You investigate R&D too, finding possibilities for technological and commercial advances. See there what the future holds.
Companies and 2018 market value What happens next? Our report predicts the world market for biomarker systems will reach $29.25bn in 2018 - with high growth - and expand further to 2023. Find how high revenues can go.
Our work also shows you what technologies and organisations hold greatest potential. See profiles of 25 companies. First you examine contract service providers (CROs), including these:• Quintiles• Covance• Parexel• Charles River Laboratories• ICON• WuXi AppTec.
Next you assess technology providers, including these companies:
• Life Technologies
• Thermo Fisher Scientific.
Then, for diagnostic testing systems, you examine developers and producers including these:• Quest Diagnostics• Myriad Genetics• Genomic Health• Critical Diagnostics• MDxHealth.
There you analyse participants' results, capabilities, and outlooks. You find 210 organisations mentioned
Copyright©2012 PR Newswire.
All rights reserved